 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- |||| AdimrSC-2f / Adimmune
Trial completion: Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - Jul 31, 2023
P1/2, N=241, Completed, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed
- ||| AdimrSC-2f / Adimmune
Enrollment closed, Trial completion date, Trial primary completion date: Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - Jan 9, 2023
P1/2, N=240, Active, not recruiting, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
- |||| AdimrSC-2f / Adimmune
Enrollment open: Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - May 26, 2022
P1/2, N=240, Recruiting, Sponsor: Adimmune Corporation
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- ||| AdimrSC-2f / Adimmune
Trial completion: A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - May 24, 2022
P1, N=68, Completed, Sponsor: Adimmune Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| AdimrSC-2f / Adimmune
New P1/2 trial: Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - Nov 3, 2021
P1/2, N=240, Not yet recruiting, Sponsor: Adimmune Corporation
- || AdimrSC-2f / Adimmune
Enrollment closed, Trial completion date: A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - Oct 18, 2021
P1, N=70, Active, not recruiting, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Oct 2021
- | AdimrSC-2f / Adimmune
Trial completion date: A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - Jul 21, 2021
P1, N=70, Recruiting, Sponsor: Adimmune Corporation
Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Oct 2021 Trial completion date: Mar 2021 --> Jul 2021
- ||| AdimrSC-2f / Adimmune
New P1 trial: A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - Aug 20, 2020
P1, N=70, Recruiting, Sponsor: Adimmune Corporation